Structural Characterization of Amorfrutins Bound to the Peroxisome Proliferator-Activated Receptor γ

被引:53
|
作者
de Groot, Jens C. [1 ]
Weidner, Christopher [2 ]
Krausze, Joern [1 ]
Kawamoto, Ken [3 ,4 ]
Schroeder, Frank C. [3 ,4 ]
Sauer, Sascha [2 ]
Buessow, Konrad [1 ]
机构
[1] Helmholtz Ctr Infect Res, Dept Mol Struct Biol, D-38214 Braunschweig, Germany
[2] Max Planck Inst Mol Genet, Otto Warburg Lab, D-14195 Berlin, Germany
[3] Cornell Univ, Boyce Thompson Inst, Ithaca, NY USA
[4] Cornell Univ, Dept Chem & Chem Biol, Ithaca, NY USA
关键词
PPAR-GAMMA; LIGAND-BINDING; FATTY-ACID; MECHANISM; AGONISTS; PROGRAM; ALPHA; SET;
D O I
10.1021/jm3013272
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Amorfrutins are a family of natural products with high affinity to the peroxisome proliferator-activated receptor gamma (PPAR gamma), a nuclear receptor regulating lipid and glucose metabolism. The PPAR gamma agonist rosiglitazone increases insulin sensitivity and is effective against type II diabetes but has severe adverse effects including weight gain. Amorfrutins improve insulin sensitivity and dyslipidemia but do not enhance undesired fat storage. They bear potential as therapeutics or prophylactic dietary supplements. We identified amorfrutin B as a novel partial agonist of PPAR gamma with a considerably higher affinity than that of previously reported amorfrutins, similar to that of rosiglitazone. Crystal structures reveal the geranyl side chain of amorfrutin B as the cause of its particularly high affinity. Typical for partial agonists, amorfrutins 1, 2, and B bind helix H3 and the beta-sheet of PPARy gamma but not helix H12.
引用
收藏
页码:1535 / 1543
页数:9
相关论文
共 50 条
  • [1] Characterization of the mouse peroxisome proliferator-activated receptor δ gene
    Magge, SS
    Guardiola-Diaz, HM
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2002, 290 (01) : 230 - 235
  • [2] Peroxisome proliferator-activated receptor γ and atherosclerosis
    Marx, N
    [J]. CURRENT HYPERTENSION REPORTS, 2002, 4 (01) : 71 - 77
  • [3] Peroxisome proliferator-activated receptor agonists
    Willson, TM
    Wahli, W
    [J]. CURRENT OPINION IN CHEMICAL BIOLOGY, 1997, 1 (02) : 235 - 241
  • [4] Peroxisome proliferator-activated receptor γ and cancers
    Koeffler, HP
    [J]. CLINICAL CANCER RESEARCH, 2003, 9 (01) : 1 - 9
  • [5] Chondrosarcoma and Peroxisome Proliferator-Activated Receptor
    Nishida, K.
    Kunisada, T.
    Shen, Z. N.
    Kadota, Y.
    Hashizume, K.
    Ozaki, T.
    [J]. PPAR RESEARCH, 2008, 2008
  • [6] Structural basis for specific ligation of the peroxisome proliferator-activated receptor δ
    Wu, Chyuan-Chuan
    Baiga, Thomas J.
    Downes, Michael
    La Clair, James J.
    Atkins, Annette R.
    Richard, Stephane B.
    Fan, Weiwei
    Stockley-Noel, Theresa A.
    Bowman, Marianne E.
    Noel, Joseph P.
    Evans, Ronald M.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2017, 114 (13) : E2563 - E2570
  • [7] Peroxisome proliferator-activated receptor γ and atherosclerosis
    Nikolaus Marx
    [J]. Current Hypertension Reports, 2002, 4 : 71 - 77
  • [8] STRUCTURAL AND METABOLIC REQUIREMENTS FOR ACTIVATORS OF THE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR
    GOTTLICHER, M
    DEMOZ, A
    SVENSSON, D
    TOLLET, P
    BERGE, RK
    GUSTAFSSON, JA
    [J]. BIOCHEMICAL PHARMACOLOGY, 1993, 46 (12) : 2177 - 2184
  • [9] Selective peroxisome proliferator-activated receptorα modulators (SPPARMα): The next generation of peroxisome proliferator-activated receptor α-agonists
    Jean-Charles Fruchart
    [J]. Cardiovascular Diabetology, 12
  • [10] Peroxisome proliferator-activated receptor α-independent peroxisome proliferation
    Zhang, Xiuguo
    Tanaka, Naoki
    Nakajuna, Takero
    Kamijo, Yuji
    Gonzalez, Frank J.
    Aoyama, Toshifumi
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2006, 346 (04) : 1307 - 1311